Hereditary angioedema (HAE) is a debilitating condition caused by a functional C1-inhibitor (C1-INH) deficiency and characterized clinically by episodes of subcutaneous or submucosal swelling. C1-INH replacement is highly effective for preventing HAE attacks and can improve health-related quality of life. Once available only for intravenous use, C1-INH is now available as a subcutaneous formulation for self-administration, shown to provide sustained plasma levels of C1-INH and reducing the monthly median HAE attack rate by 95% versus placebo in the phase 3 COMPACT study. Subcutaneously administered C1-INH satisfies multiple unmet needs in the management of patients with HAE. Reference: Lumry, W., Templeton, T., Omert, L. and Levy, D. (2020) Advances in Hereditary Angioedema: The Prevention of Angioedema Attacks With Subcutaneous C1-Inhibitor Replacement Therapy. Journal of Infusion Nursing. 43(3), p. 134-145. doi: 10.1097/NAN.0000000000000365.
About IVTEAM citation library
IVTEAM has established itself as a core global resource for infusion and vascular access practitioners. Each day 6K users have access thousands of pages of easy to access relevant intravenous news and updates. IVTEAM offers its visitors a premier service that has no financial or subscriber based restrictions. The editorial stance of IVTEAM is to ensure no editorial restrictions exist; content remains unbiased and independent.
It is crucial that IVTEAM stays up-to-date and offers visitors regular, current updates. Each day news feeds are analysed, websites searched and various additional sources of information visited. This results in large amounts of data being sifted through for relevant information every day. Only a small amount of data is relevant to IV practice and makes it onto IVTEAM.